ArriVent BioPharma, Inc.
Nasdaq: AVBPPharmaceutical Preparations · Entity-resolved by Clous
CIK0001868279
TickerAVBP
ExchangeNasdaq
SIC2834
StateDE
FY end12-31
Key financials
Revenue
—
—
Net IncomeFY2025-12-31
-$166.31M
-106.6% YoY
Total AssetsFY2025-12-31
$333.17M
+21.2% YoY
EquityFY2025-12-31
$307.22M
+19.2% YoY
Shares OutstandingFY2025-12-31
44.2M
—
Operating Cash FlowFY2025-12-31
-$160.59M
-128.7% YoY
Market
Market
AVBPClose price
$31.74
Market cap
$1.48B
delayed EOD · as of 2026-06-18
Short interest & fails
Short-sale volume
FINRA Reg SHO · daily59.4%
short of total volume · 2026-06-18
2026-06-1859.4%
2026-06-1739.5%
2026-06-1675.8%
2026-06-1560.0%
2026-06-1258.5%
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
ArriVent BioPharma disclosed a Silicon Valley Bank loan agreement with multiple term‑loan tranches (Tranche One, Two, Three) dated May 8 2025.
What it means
The company has taken on additional debt, increasing liquidity but also adding repayment obligations and covenant exposure.
What to watch
Monitor covenant compliance, repayment schedule, and any refinancing needs.
Generated from public filings · not investment advice
| Concept | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|
| Net Income | -$80.49M | -$166.31M | -106.6% | — |
| Total Assets | $274.94M | $333.17M | +21.2% | — |
| Equity | $257.65M | $307.22M | +19.2% | — |
| Operating Cash Flow | -$70.21M | -$160.59M | -128.7% | — |
| Shares Outstanding | — | 44.2M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001868279